Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002976 · ClinicalTrials.gov registry record · Phase 3
Estrogen Replacement Therapy in Treating Women With Early-Stage Endometrial Cancer
A Phase 3 study, sponsored by Gynecologic Oncology Group.
- Terminated
- Registry status
- Phase 3
- Development phase
- 2,108
- Enrollment target
NCT00002976 is a Phase 3 study that was terminated before completion, run by Gynecologic Oncology Group. The registered enrollment target is 2,108 participants.
The verdict
NCT00002976, a Phase 3 study, was terminated before completion, sponsored by Gynecologic Oncology Group.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2,108 participants
- Enrollment target
Study Summary
RATIONALE: Estrogen replacement therapy may improve quality-of-life in postmenopausal women with endometrial cancer. It is not yet known whether estrogen replacement therapy will affect cancer recurrence. PURPOSE: Randomized double-blinded phase III trial to determine the effectiveness of estrogen replacement therapy in treating women who have stage I or stage II endometrial cancer.
Interventions
- DRUG conjugated estrogens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,108 participants |
| Start Date | 1997-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002976
The ClinicalTrials.gov registry entry for NCT00002976 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 2,108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which conjugated estrogens is the first listed.
NCT00002976 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002976 about?
NCT00002976 is a clinical study titled "Estrogen Replacement Therapy in Treating Women With Early-Stage Endometrial Cancer". RATIONALE: Estrogen replacement therapy may improve quality-of-life in postmenopausal women with endometrial cancer. It is not yet known whether estrogen replacement therapy will affect cancer recurrence. PURPOSE: Randomized double-blinded phase III trial to determine the effectiveness of estrogen ...
What is the current status of trial NCT00002976?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2,108 participants. The study started on 1997-06.
What interventions are being tested in trial NCT00002976?
The interventions under investigation include: conjugated estrogens (DRUG).
Who is sponsoring clinical trial NCT00002976?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.